Oculis Holding AG (OCS) Non-Current Assets (2021 - 2026)
Oculis Holding AG (OCS) recorded quarterly Non-Current Assets of $21.7 million in Q1 2026, up 1.36% quarter-over-quarter from $21.4 million in Q4 2025, and up 26.56% on a YoY basis from $17.1 million in Q1 2025.
Oculis Holding AG (OCS) Non-Current Assets (2021 - 2026) Analysis & Trends
Oculis Holding AG's Non-Current Assets history runs 6 years deep, the most recent figure standing at $21.7 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 26.56% year-over-year to $21.7 million; the TTM figure through Mar 2026 stood at $21.7 million (up 26.56% YoY), while the FY2025 annual figure was $21.4 million, up 21.08% from the prior year.
- Non-Current Assets was $21.7 million for Q1 2026 at Oculis Holding AG, up from $21.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $21.7 million in Q1 2026 to a low of $13.9 million in Q4 2022.
- Historically, Non-Current Assets has averaged $17.2 million across 5 years, with a median of $16.3 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets increased 4.02% in 2024, then grew 29.88% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $13.9 million in 2022, then grew by 8.08% to $15.0 million in 2023, then grew by 17.34% to $17.6 million in 2024, then advanced by 21.08% to $21.4 million in 2025, then climbed by 1.36% to $21.7 million in 2026.
- The last three Non-Current Assets figures came in at $21.7 million (Q1 2026), $21.4 million (Q4 2025), and $21.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 62,953.78 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 39.71 Mn |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | 21.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.65 Mn |
| Dec 31, 2025 | 21.36 Mn |
| Sep 30, 2025 | 21.16 Mn |
| Jun 30, 2025 | 18.63 Mn |
| Mar 31, 2025 | 17.11 Mn |
| Dec 31, 2024 | 17.64 Mn |
| Sep 30, 2024 | 16.29 Mn |
| Jun 30, 2024 | 15.59 Mn |
| Mar 31, 2024 | 15.20 Mn |
| Dec 31, 2023 | 15.04 Mn |
| Sep 30, 2023 | 15.22 Mn |
| Jun 30, 2023 | 14.99 Mn |
| Dec 31, 2022 | 13.91 Mn |
| Dec 31, 2021 | 10.91 Mn |